<?xml version="1.0" encoding="UTF-8"?>
<p id="Par14">We further performed a subgroup analysis from the timing of usage before the third trimester. As respected, either AVT at ~ 14 weeks or between 14 and 28 weeks showed significant efficacy in interrupting MTCT separately when comparing with untreated pregnant female (Fig. S2a, b).</p>
